In Q3 FY2022 (ended September 30, 2021), Atea Pharmaceuticals reported revenue of $32.8 million. Net loss was $45.4 million, a 32.6% increase year-over-year. Operating loss was $48.0 million, up 23.0% from the prior year. Diluted EPS was -$0.57, compared to -$0.40 in the same quarter last year.
•Revenue of $32.8 million in Q3 FY2022.
•Net loss of $45.4 million, widening 32.6% year-over-year.
•Operating loss of $48.0 million, up 23.0%.
•Diluted EPS of -$0.57, a 42.5% decline from prior year.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers develops, and commercializes oral antiviral therapeutics for patients with serious viral infections.
Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV).
It also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development.
The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Incorporated in 2012, Atea Pharmaceuticals is headquartered in Boston, Massachusetts.
Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is a regimen combining bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, currently in Phase 3 clinical trials for the treatment of hepatitis C virus (HCV). The company is also developing AT-587, a candidate in Phase 1 trials for chronic HEV infection, and maintains a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. Atea has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir.
Where is Atea Pharmaceuticals (AVIR) listed and what currency does it trade in?
Atea Pharmaceuticals, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol AVIR. The company trades in U.S. dollars (USD), as it is headquartered in the United States. Being listed on NasdaqGS provides the company with access to a broad base of institutional and retail investors, and its shares are traded during regular market hours. The exchange listing and currency are standard for U.S.-based biopharmaceutical companies, and investors can buy and sell AVIR shares through any brokerage that offers access to Nasdaq-listed securities.
What sector and industry does Atea Pharmaceuticals (AVIR) belong to?
Atea Pharmaceuticals operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, Atea focuses on developing innovative therapies using biological and chemical processes, particularly oral antiviral drugs. The company's work in virology and its clinical-stage pipeline place it squarely in the biotech space, which is characterized by high research and development costs, regulatory milestones, and potential for significant returns upon successful commercialization. The Healthcare sector encompasses a wide range of companies, but Atea's specialization in antivirals for serious viral infections distinguishes it within the broader biotech industry.
Where is Atea Pharmaceuticals (AVIR) headquartered and what markets does it serve?
Atea Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts, United States. The company was incorporated in 2012 and primarily serves the global market for antiviral therapeutics, with a focus on serious viral infections such as hepatitis C virus (HCV) and hepatitis E virus (HEV). While its operations are based in the U.S., its clinical trials and potential future commercial activities may extend to international markets. The license agreement with MSD International GmbH, a subsidiary of Merck & Co., indicates a global collaboration for the development and commercialization of ruzasvir, one of its key product candidates. Boston is a major hub for biotechnology and pharmaceutical research, providing access to talent and resources.
What is the business model of Atea Pharmaceuticals (AVIR) and how does it generate revenue?
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company, meaning it does not yet have approved products on the market and currently generates no revenue from product sales. Its business model revolves around discovering and developing oral antiviral therapeutics through internal research and external collaborations. The company's lead candidate, a regimen of bemnifosbuvir and ruzasvir for HCV, is in Phase 3 trials, and it also has an early-stage candidate, AT-587, for HEV. Atea has a license agreement with MSD International GmbH for ruzasvir, which may include milestone payments and royalties. Future revenue will depend on successful clinical development, regulatory approval, and commercialization of its pipeline. The company also leverages its proprietary platform of nucleosides and nucleotides to create new antiviral candidates.